Rachel Froehlich
Medical · Pomona, NYNPI 1538393988
Payments from drug & device makers
Across 85 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$282
- Amgen$185
- AbbVie$134
- Boehringer Ingelheim$120
- Novo Nordisk$117
- Pfizer$108
- plus $914 from 23 others
What the payments were for
- Food & beverage$1,861100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 10 | $282 |
| Amgen(2 entities) | 8 | $185 |
| AbbVie | 6 | $134 |
| Boehringer Ingelheim | 6 | $120 |
| Novo Nordisk | 7 | $117 |
| Pfizer | 5 | $108 |
| Ascendis Pharma Endocrinology Inc | 4 | $91 |
| Corcept Therapeutics | 5 | $83 |
| Lilly USA, LLC | 4 | $78 |
| Medtronic | 3 | $74 |
| Chiesi USA, Inc. | 3 | $68 |
| Recordati_rare_diseases_inc. | 3 | $61 |
| Almatica Pharma LLC | 2 | $60 |
| Radius Health, Inc. | 2 | $45 |
| Astellas Pharma US Inc | 2 | $40 |
| Neurocrine Biosciences, Inc. | 1 | $30 |
| Embecta Corp. | 1 | $28 |
| Alvogen Inc | 1 | $27 |
| Acella Pharmaceuticals, LLC | 2 | $27 |
| Soleno Therapeutics, Inc. | 1 | $26 |
| Madrigal Pharmaceuticals | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Rhythm Pharmaceuticals, Inc. | 1 | $22 |
| GSK | 1 | $21 |
| Mannkind Corporation | 1 | $18 |
| Bayer | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
How this compares
$1,861 in reported general payments places this provider in the 75th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 62 | $41,302 |
| MounjaroTirzepatide | 36 | $38,406 |
| OzempicSemaglutide | 33 | $29,724 |
| TradjentaLinagliptin | 41 | $21,101 |
| TrulicityDulaglutide | 19 | $18,752 |
| RybelsusSemaglutide | 19 | $17,284 |
| FarxigaDapagliflozin Propanediol | 11 | $5,994 |
| SynthroidLevothyroxine Sodium | 28 | $2,501 |
| Levothyroxine Sodium | 84 | $1,860 |
| Repaglinide | 20 | $403 |
| Metformin Hcl | 33 | $277 |
| Metformin Hcl ErMetformin Hcl | 25 | $138 |
| Atorvastatin Calcium | 23 | $111 |
| Furosemide | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $120 | $62,402103 claims |
| Lilly USA, LLCMounjaro, Trulicity | $78 | $57,15855 claims |
| Novo NordiskOzempic, Rybelsus | $117 | $47,00852 claims |
| AbbVieSynthroid | $134 | $2,50128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,395 medical providers in New York.
Other medical in Pomona
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
- Hailey BrickmanNew York$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.